Home›Stock Screener›Hester Biosciences

Hester Biosciences Share Price Today | Stock Price & Hester Biosciences Share Screener

HESTERBIO Pharmaceuticals & Biotechnology
Live Share Price NSE
₹2352.10
▲ 4.10 (0.17%)
2026-11-19 00:00:00
Live Share Price BSE
₹2346.10
▲ 12.80 (0.55%)
2026-11-19 00:00:00

As of November 19, 2026, the live Hester Biosciences share price (NSE: HESTERBIO) is ₹2,352.10 on NSE and ₹2,346.10 on BSE, up 0.17% from the previous close, with shares trading between ₹2,329.00 and ₹2,424.00 in today's trading session, and a 52-week range of ₹1,259.10–₹2,545.00. Track HESTERBIO company valuation to gauge the company's total market size. Use the Hester Biosciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Hester Biosciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹102 and net income of ₹17, with EBITDA of ₹36, an operating margin of 34.0% and a profit margin of 16.7%.

Hester Biosciences Market Cap ₹1,976.66 Cr.
HESTERBIO P/E Ratio (TTM) 13.90
Hester Biosciences P/B Ratio 4.24
EPS (TTM) ₹67.57
Dividend Yield 0.47%
Debt to Equity 0.60
HESTERBIO 52 Week High ₹2545.00
Hester Biosciences 52 Week Low ₹1259.10
Operating Margin 34.00%
Profit Margin 16.67%
HESTERBIO Revenue (TTM) ₹102.00
EBITDA ₹36.00
Net Income ₹17.00
Total Assets ₹678.00
Total Equity ₹368.00

Hester Biosciences Share Price Chart

Track the current stock price of Hester Biosciences with an interactive chart. Analyse HESTERBIO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Hester Biosciences stock quote in one place.

The quote of ₹2,352.10 sits between the 52-week low of ₹1,259.10 and the 52-week high of ₹2,545.00, and the latest session moved 0.17% from the previous close.

Hester Biosciences Company Profile - Fundamental Screener

Screen Hester Biosciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for HESTERBIO shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE782E01017.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE782E01017

Hester Biosciences Balance Sheet Screener

Screen HESTERBIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹678, up from ₹653 in 2025.

Latest statistics put total assets at ₹678 and shareholder funds at ₹368, with a leverage ratio of 0.60.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 678 653 662 670 562 411 387 300 244 213
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 412 233 240 259 237 133 142 145 110 103

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 158 202 254 233 198 114 97 70 44 48
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 368 327 303 289 267 236 207 181 145 127
Share Capital 9 9 9 9 9 9 9 9 9 9
Reserves & Surplus 352 306 283 271 252 220 193 169 132 113

Hester Biosciences Income Statement Screener - Profit & Revenue Analysis

Screen Hester Biosciences income statement and profit fundamentals. Analyze HESTERBIO quarterly results. Hester Biosciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹102 and net profit was ₹17, equal to earnings per unit of ₹19.45, at an operating margin of 34%.

In that period expenses were ₹66, interest cost ₹5 and tax ₹9. The next period listed, 2026-Jun, shows revenue of ₹166 and net profit of ₹97.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 102 166 102 76 88 83 79 84 84 87 72 71 90 76 69
Expenses 66 55 65 63 61 59 60 63 65 65 58 56 74 57 57

Operating Costs and Margins

EBITDA 36 112 37 14 26 24 20 21 20 22 14 15 17 19 12
Operating Profit % 34.00% 29.00% 33.00% 23.00% 27.00% 17.00% 23.00% 20.00% 21.00% 23.00% 8.00% 17.00% 16.00% 19.00% 15.00%
Depreciation 6 7 7 4 4 4 4 4 4 4 4 5 5 4 4
Interest 5 3 3 6 2 2 2 7 5 6 -4 1 3 8 2

Profit and Earnings

Profit Before Tax 25 102 27 4 20 17 14 10 11 12 13 8 9 7 6
Tax 9 5 6 2 3 3 4 4 3 4 2 3 2 3 2
Net Profit 17 97 21 2 17 14 9 6 8 8 11 6 7 4 4
EPS 19.45 113.71 23.94 1.82 20.33 16.85 10.94 7.52 8.80 9.86 13.41 6.72 7.89 4.75 4.73

Hester Biosciences Cash Flow Screener - Liquidity Fundamentals

Screen HESTERBIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹64, and net cash flow was an outflow of ₹3.

Over the same period, investing activities used ₹18 and financing activities used ₹49.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 64 65 48 24 9 58 37 47 38 35
Investing Activities -18 -20 -23 -77 -117 -42 -73 -21 -26 -30

Financing and Net Cash

Financing Activities -49 -52 -26 42 112 -18 19 3 -11 2
Net Cash Flow -3 -7 0 -12 4 -2 -17 28 1 6

Hester Biosciences Shareholding Pattern Screener

See Hester Biosciences shareholding pattern with promoter, FII, and DII holdings. Check Hester Biosciences promoter holding and ownership changes for HESTERBIO on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 53.73%, foreign institutions 0.38%, domestic institutions 0.00% and the public 33.29%, spread across 12,373 shareholders.

The shareholder count was 12,373 in 2026-Mar, compared with 11,961 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 53.73% 53.73% 44.28% 53.73% 53.73% 53.73% 53.73% 53.73%

Institutional Investors

FII Holding 0.38% 0.31% 0.31% 0.87% 0.52% 0.53% 0.51% 0.43%
DII Holding 0.00% 0.00% 0.08% 0.02% 0.02% 0.00% 0.01% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 33.29% 33.00% 32.70% 32.64% 32.80% 32.92% 33.06% 33.32%
Other Holding 12.60% 12.95% 22.63% 12.73% 12.93% 12.82% 12.68% 12.52%
Shareholder Count 12,373 11,961 11,685 11,853 11,810 12,260 12,603 12,844

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Hester Biosciences. Hester Biosciences dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹11.00 per unit for 2026-March, a yield of 0.47%, compared with ₹7.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹11.00, ₹7.00 and ₹6.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹11.00 0.47%
2025-March ₹7.00 0.56%
2024-March ₹6.00 0.48%
2023-March ₹8.00 0.57%
2022-March ₹10.00 0.64%
2021-March ₹10.00 0.37%
2020-March ₹6.60 0.34%
2019-March ₹11.00 1.20%
2018-March ₹10.00 0.65%
2017-March ₹5.30 0.33%

Hester Biosciences Stock Index Membership - Nifty & Sensex

See which indices include Hester Biosciences stock. Check HESTERBIO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 3 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP

Hester Biosciences Market Events Screener - Corporate Actions

Get Hester Biosciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Hester Biosciences stock events that may affect HESTERBIO share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.

It is followed by Quarterly Result Announcement dated July 30, 2026 and Annual General Meeting dated July 21, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-05 2026-11-05 Quarterly Result Announcement NA 12.50%
2026-07-30 2026-07-30 Quarterly Result Announcement NA 2.58%
2026-07-21 2026-07-21 Annual General Meeting NA 22.94%
2026-07-14 2026-07-14 Dividend ₹ 11.00 /share 45.84%
2026-05-15 2026-05-15 Quarterly Result Announcement NA 5.96%
2026-01-30 2026-01-30 Quarterly Result Announcement NA 1.41%
2025-11-12 2025-11-12 Quarterly Result Announcement NA 0.69%
2025-08-13 2025-08-13 Annual General Meeting NA 7.94%
2025-08-06 2025-08-06 Dividend ₹ 7.00 /share 19.29%
2025-08-01 2025-08-01 Quarterly Result Announcement NA 3.70%
2025-05-09 2025-05-09 Quarterly Result Announcement NA -4.77%
2025-01-30 2025-01-30 Quarterly Result Announcement NA -4.79%
2024-10-28 2024-10-28 Quarterly Result Announcement NA -8.20%
2024-08-29 2024-08-29 Annual General Meeting NA -22.24%
2024-08-22 2024-08-23 Dividend ₹ 6.00 /share 52.21%

Hester Biosciences Competitors Screener - Peer Stocks Comparison

Screen HESTERBIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.20 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.40 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,632 85.50 13,886 20.34% 2,138 47.27
Laurus Labs 130,972 97.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 28.00 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 42.00 35,059 3.90% 4,158 70.24
Cipla 112,438 39.90 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.10 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,903 26.00 34,145 5.56% 3,503 66.06
Lupin 90,557 17.60 29,039 26.75% 5,356 44.92

Hester Biosciences Company Announcements - News & Reports Screener

Screen HESTERBIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 12, 2026.

The next most recent announcements are dated November 11, 2026 and November 10, 2026.

Date Update Actions
2026-11-12 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-11 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-10 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-10 Announcement Under Regulation 30 Of Listing Regulations - Approved An Unsecured Loan To Foreign Wholly-Owned Subsidiary -
2026-11-10 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-10 Board Meeting Outcome for Outcome Of Board Meeting And Financial Results -
2026-10-28 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-27 Board Meeting Intimation for Financial Results -
2026-10-27 Announcement Under Regulations 30 (LODR) - Completion Of Tenure Of Independent Director -
2026-10-14 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-06 Disclosure Under Regulation 30 Of The SEBI Listing Regulations For Investment In Limited Liability Partnership For Group Captive Power Generation -
2026-10-06 Board Meeting Outcome for Outcome Of Board Meeting Held Today -
2026-09-25 Closure of Trading Window -
2026-09-04 Shareholders Approval For Reclassification From Promoter And Promoter Group Category To Public Category Shareholders -
2026-09-04 Shareholder Meeting / Postal Ballot-Scrutinizer"s Report -
2026-09-04 Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot -
2026-08-27 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-08-04 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot -
2026-08-01 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-07-31 Launch Of Interactive Microsite Of 39Th Annual Report FY 2025-26 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹2,352.10, within a 52-week range of ₹1,259.10 to ₹2,545.00. The P/E ratio is 13.90 and the P/B ratio is 4.24, with earnings per unit of ₹67.57. Market capitalisation stands at ₹1,976.66 Cr and the dividend yield is 0.47%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.